Objectives:
1. Understand how DNA repair defects lead to genetic instability and cancer
2. Explain how DNA repair defects are relevant to prostate cancer prognosis and management
3. Discuss treatment of patients with metastatic castrate resistant prostate cancer with PARP inhibitors
and
1. Use of novel predictive biomarkers for aGVHD
2. Initial management of aGVHD
3. Utility of Ruxolitinib and Extracorporeal Photopheresis in the management of steroid-refractory aGVHD
Session date:
08/21/2017 - 12:00pm to 1:00pm CDT
Location:
UCMC
Chicago, IL
60637
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Marquita Nelson, MD and Benjamin Derman, MD